81
Participants
Start Date
March 31, 2002
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
OSI-774: erlotinib, TarcevaTM
150 mg, 100 mg and 25 mg tablets
Memorial Sloan Kettering Cancer Center, New York
Collaborators (1)
M.D. Anderson Cancer Center
OTHER
Northwestern University
OTHER
Vanderbilt-Ingram Cancer Center
OTHER
Dana-Farber Cancer Institute
OTHER
Genentech, Inc.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER